US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...

Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...

Sotyktu (deucravacitinib) is a brand-name oral tablet that’s prescribed for plaque psoriasis in certain adults. As with other drugs, Sotyktu can cause side effects. These include cancer and ...

Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...

Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Bristol Myers Squibb (BMS) has announced positive topline results from two Phase III trials evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic ...

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment ...